CAR-T Cell Therapy: A Revolutionary Approach to Cancer Treatment

Mar 10, 2026

Engineered T cells are framed as precision soldiers attacking cancer with detailed clinical workflow steps. The show highlights striking successes in blood cancers and early efforts against solid tumors. Serious toxicities, therapy resistance, and access inequalities are discussed. Future developments include safety switches, donor-derived products, and platform improvements.

Ask episode

AI Snips

Chapters

Transcript

Episode notes

INSIGHT

How CAR T Cells Are Made And Deployed

CAR T therapy engineers a patient's T cells to express chimeric antigen receptors that directly target tumor antigens.
Clinically it involves leukapheresis, ex vivo CAR gene editing and expansion over weeks, then infusion after chemotherapy to improve engraftment.

INSIGHT

Proven Success In Blood Cancers And Early Solid Tumor Gains

CAR T has produced remarkable responses in hematologic cancers and is moving toward second-line use in non-Hodgkin lymphoma.
Early Phase 1 reports show measurable activity in glioblastoma and breast cancer, indicating progress in solid tumor applications.

INSIGHT

Toxicities And Solid Tumor Barriers Limit CAR T Impact

Major clinical risks include cytokine release syndrome and neurotoxicity driven by massive inflammatory cytokine release from activated CAR T cells.
Solid tumors add barriers: few tumor-specific antigens, immunosuppressive microenvironments, and poor CAR T trafficking to tumor sites.

Get the Snipd Podcast app to discover more snips from this episode

Get the app

Cancer treatment has long been a battle of attrition—surgery, radiation, and chemotherapy have saved countless lives, but for patients with advanced or refractory malignancies, the options remain limited. In recent years, however, a new approach has emerged that harnesses the power of the patient’s own immune system to seek and destroy cancer cells with unprecedented precision. An editorial perspective, titled “CAR-T therapy: Trailblazing CAR(ing) in cancer treatment.” published in Volume 17 of Oncotarget by researchers Uzma Saqib, Monika Pandey, and Krishnan Hajela from the School of Life Sciences, Devi Ahilya Vishwavidyalaya, Indore, India, provides an overview of this revolutionary therapeutic strategy. The paper presents the current state of CAR-T therapy, its clinical successes, and the formidable challenges that remain before it can fulfill its transformative potential. Full blog - https://www.oncotarget.org/2026/03/10/car-t-cell-therapy-a-revolutionary-approach-to-cancer-treatment/ Paper DOI - https://doi.org/10.18632/oncotarget.28836 Correspondence to - Krishnan Hajela - hajelak@gmail.com Abstract video - https://www.youtube.com/watch?v=T4hbwPToVKI Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28836 Subscribe for free publication alerts from Oncotarget - https://www.oncotarget.com/subscribe/ Keywords - cancer, CAR-T therapy, therapeutic approaches To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us: Facebook - https://www.facebook.com/Oncotarget/ X - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/@OncotargetJournal LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Spotify - https://open.spotify.com/show/0gRwT6BqYWJzxzmjPJwtVh MEDIA@IMPACTJOURNALS.COM